Current Position:  English  
Key Disciplines
Provincial Key Specialty  
Key Clinical Specialty of Jiangsu Province--Oncology Department
Published:jdfy Release time:2016-11-24 14:28 Read:times

【Profile】

Oncology Department is the Key Clinical Specialty of Jiangsu province, National Drug Clinical Trial Base, master degree conferment institute on oncology and the clinical multi-center training base of Chinese Anti Cancer Association. It has developed into a clinical treatment and scientific research complex composed of four major departments, namely, the Radiotherapy Department, Chemotherapy Department,CellTherapyCenterand Oncology Laboratory.

 

 

Radiotherapy Department provides 160 beds open for patients and has a medical force over twenty doctors. Presently, it is the largest specialty inZhenjiangwith the largest inpatient capacity and the most talented staff structure. We have introduced the most advanced technology and equipments, such as the Cobalt 60 Therapeutic Machine of GE Company, France, After-loading Therapy Equipment, Varian 23 EX High-energy Linear Accelerator, Radiotherapy Treatment Planning System, Varian Simulation Positioning Machine and Radiofrequency Ablation Treatment Machine based on Cool-Tip RF System. In 2014, we introduced the most advanced intensity modulated radiation therapy (IMRT) and Stereotactic radiotherapy (SRT) system, namely, the TrueBeam, pushing our ability of radiotherapy forwards to the advanced level nationwide.

 

 

Chemotherapy Department, as an independent specialty since 1985, is one of the earliest established tumor chemotherapy departments. It provides over 80 beds open for patients and has a medical force of thirteen doctors. Among them, there are four chief or associate chief doctors, five attending doctors, four resident doctors. And two of them obtained doctoral degree, five of them obtained master degree, and one of them is postgraduate supervisor. We started enrolling postgraduates since 2014. Most of the doctors have received standardized training in tumor hospital inShanghaiorNanjing. Three of the doctors are the members of provincial and municipal Chemotherapy Professional Committee. What is more, one of our doctors is one of the ‘169 talents’.

 

【Technical Features】

With the integration of cell therapy, biological targeted therapy, endocrine therapy, the combination of Chinese traditional and Western medicine and non surgical treatment of tumors, the department has made great achievements in treating malignant lymphoma, mammary cancer, head-neck tumor and several kinds of therioma in connection with respiration, digestion, genitourinary system, and bone and soft tissue. This department has operated the Three-step Analgesic Ladder for Cancer Pain in the early years. At present, the department has presided over and accomplished several national and provincial projects. Our staffs have published several high-level theses in some domestic and international leading magazines, some of them are indexed by SCI and received prize for science and technology progress awarded by provincial and municipal scientific authorities. What is more, this department also undertakes the tasks of medical education, guidance for advanced studies and internship. We also have carried out several drug clinical trials.

 

The TrueBeam represents the most advanced radiotherapy technology in the world. It can destroy the “central nerve system” of tumor by concentrated and intensified X-ray and restrain the duplication of tumor cells. It can precisely treat different kinds of cancers, such as head-neck tumor, lung cancer, esophageal cancer, prostatic cancer, rectal cancer, gastric cancer, primary carcinoma of liver, cervical cancer and endometrial carcinoma. TrueBeam can ensure high precision and high efficacy of tumor treatment, shorten the treatment time effectively and bring new hope to those patients who initially would be hopeless in their treatment. With the operation of TrueBeam, the treatment of tumor in our hospital and the research of oncology inZhenjianghave been improved greatly, bringing good news to tumor patients.

 

 

Department of Chemotherapy have explored and established a set of complex treatment strategies and chemotherapy routine. We keep applying new medicine, new technology and new methods, and have dramatically improved the effective rate and cure rate of malignant tumor treatment. Many tumor patients have made good recovery under our careful treatment. We operate the chemotherapy after radical operation, neoadjuvant chemotherapy, adjuvant chemotherapy and palliative chemotherapy; With the integration of cell therapy, endocrine therapy, the combination of Chinese traditional and Western medicine and non surgical treatment of tumors, the department have made great achievements in treating malignant lymphoma, mammary cancer, head-neck tumor and several kinds of therioma in connection with respiration, digestion, genitourinary system, and bone and soft tissue. The treatment reaches advanced level nationwide. This department operated the Three Step Analgesic Ladder for Cancer Pain in the early years. In 2013, we were ranked as the example ward of standardized treatment of cancer pain. In the early 1990s, we have started to perform large-dose and large-volume intraperitoneal chemotherapy to treat the advanced ovarian cancer and gastric carcinoma, and started to perform thoracic injection chemotherapy and intrathecal injection; and started to perform large dose of methotrexate (MTX) to treat osteosarcoma and central nerve system lymphoma. At the early stage of this century, we have began to use low dose of 5-fluorouracil continuous intravenous injection combing cisplatin and weekly doze of docetaxel to treat advanced gastric cancer and esophageal cancer and we have carried out radiofrequency hyperthermia. In recent years, we develop the tumor-targeted therapy, cell biological therapy and chronomodulated chemotherapy. The personalized treatment according to the pharmacogenomics has achieved positive effect. Since 2005, with the application of the PICC, patients’ pain related to the treatment has been dramatically reduced. At present, we have several specialized equipments including micro pump controlled by portable computer program and chronomodulated chemotherapy pump. The Research Institute of Tumor has set up independent laboratory. This department undertakes the education task of clinical oncology forJiangsuUniversity. We have accomplished 5 clinical research projects, received five of the prize for science and technology progress awarded by provincial and municipal scientific authorities, and undertaken three projects supported by the National Natural Science Foundation of China

 

【Academic Leader】

Chen Deyu, PhD, chief doctor, postgraduates supervisor, is now the Director of Affiliated Hospital of Jiangsu University, council member of the Tumor Targeted Therapy Technology Branch of Chinese Society of Biomedical Engineering, member of Radiation Oncology Therapeutics Branch of Jiangsu Medical Association, member of Professional Committee of Nasopharyngeal Cancer of Jiangsu Anti Cancer Association, chairman of Oncology Professional Committee of Zhenjiang Medical Association, Visiting Scholar of University of Columbia, USA, and one of the key medical talents of Zhenjiang. He specializes in radiotherapy and combined treatment of radiotherapy and chemotherapy. He has presided over about ten projects of national, provincial or municipal level.

 

Dai Chunhua is the dean of the Department of Radiotherapy, PhD and associate chief doctor. He is the member of Jiangsu Anti Cancer Association and member of Oncology Professional Committee of Zhenjiang Medical Association. He has been engaged in clinical treatment and research work on Oncology since 1990 and has participated in and accomplished several provincial and municipal research projects. He has also published several theses indexed by SCI. He has accumulated rich experience in clinical treatment and research during his work. He is skilled in the radiation treatment of cancer and combined treatment of different disciplines. At present, he mainly focuses on the research of basic treatment and clinical treatment of lung cancer.

 

Li Xiaoqin is the dean of Department of Chemotherapy, master of medicine, chief doctor, supervisor of postgraduate, member of the Professional Committee of Chemotherapy and Biological Therapy of Tumor of Jiangsu province. She has been engaged in the clinical treatment and research of tumor for more than 20 years. She is skilled in kinds of chemotherapy of tumor, including biological targeted therapy and endocrine therapy. She has presided over and participated in projects supported by the Youth Fund of National Natural Science Foundation of China, China International Medical Foundation (CIMF), and several research projects supported by Jiangsu Provincial Health and Family Planning Commission, Zhenjiang Science and Technology Bureau andJiangsuUniversity. She has published over 20 pieces of theses, some of them indexed by SCI. She has received the Second Prize of Introduction of New Medicine ofJiangsuProvince, and the Second and Third Prize of Science and Technology Progress of Zhenjiang.



  • Prev: 上一篇:没有了

  • Next: 下一篇:Key Clinical Specialty of Jiangsu Province—Gastroenterology Department

  • Return to the superior
  •  
    Print this page || close window
       
    Copyright Affiliated Hospital of Jiangsu University All right reserved
    Address:No.438 Jiefang Road,Zhenjiang China,212001
    XML 地图 | Sitemap 地图